Compositions and methods for the treatment of metabolic disorders
The present invention relates to the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. Also provided are methods for the treatment and/or prevention of one or more metabolic disorders, for example, obesity or diabetes, utilizing fatostatin A and/or a derivative and/or analog thereof and/or the A-B-C tripartite compounds.
1. A compound having the chemical structure:
wherein
X is CH or C-OMe;
R 1 is H, Et, OMe or n-propyl;
Y is CH or
R 2 is OH, OMe, OEt, or -NHR 3 ;
R 3 is H, methyl, ethyl, or isopropyl;
R 4 is H, Me, F, or Cl; and
R 5 is Cl, Br, OBz, OH, OCH 2 COOMe, F, Me, NH 2 , NH-i-Pr, NHCOMe, NHSO 2 Me, NHBn,
OMe, NHBoc,
NHTs,
wherein when R 4 is H, R 5 is OBz, OH
OCH 2 COOMe NH-i-Pr, NHCOMe, NHSO Me NHBn,
OMe, NHBoc,
NHTs,
2. The compound of claim 1 , wherein R 3 is isopropyl.
3. The compound of claim 1 , wherein R 4 is H.
4. The compound of claim 1 , wherein R 5 is Cl, F, or Me.
5. The compound of claim 1 , wherein Y is CH.
6. The compound of claim 1 , wherein the chemical structure is:
wherein
X is CH or C-OMe;
R 1 is H, Et, OMe or n-propyl;
R 4 is H, Me, F, or Cl; and
R 5 is Cl, Br, OBz, OH, OCH 2 COOMe, F, Me, NH 2 , NH-i-Pr, NHCOMe, NHSO 2 Me, NHBn,
OMe, NHBoc
NHTs
wherein when R 4 is H, R 5 is OBz, OH,
OCH 2 COOMe NH-i-Pr, NHCOMe, NHSO 2 Me, NHBn,
OMe,NHBoc,
NHTs
7. The compound of claim 6 , wherein X is C-OMe and R 1 is OMe.
8. The compound of claim 6 , wherein X is CH and R 1 is H.
9. The compound of claim 6 , wherein R 5 is Cl, F, or Me.
10. The compound of claim 1 , wherein the chemical structure is:
wherein
Y is CH or
R 2 is OH, OMe, OEt, or -NHR 3 ;
R 3 is H, methyl, ethyl, or isopropyl;
R 4 is H, Me, F, or 01 ; and
R 5 is Cl, Br, OBz, OH, OCH 2 COOMe, F, Me, NH 2 , NH-i-Pr,
NHCOMe, NHSO 2 Me, NHBn,
OMe, NHBoc
NHTs,
wherein when R 4 is H, R 5 is OBz, OH,
OCH 2 COOMe NH-i-Pr, NHCOMe,NHSO 2, NHBn,
OMe, NHBoc,
NHTs,
11. The compound of claim 10 , wherein R 3 is isopropyl.
12. The compound of claim 10 , wherein R 5 is Cl, F, or Me.
13. The compound of claim 10 , wherein Y is CH.
14. The compound of claim 1 , wherein the chemical structure is:
wherein
R 2 is OH, OMe, OEt, or -NHR 3 ;
R 3 is H, methyl, ethyl, or isopropyl;
R 4 is H, Me, F, or Cl; and
R 5 is Cl, Br, OBz, OH, OCH 2 COOMe, OCH 2 COOH, F, Me, NH 2 , NH-i-Pr, NHCOMe, NHSO 2 Me, NHBn,
OMe, NHBoc,
OMe, NHBoc,
NHTs,
15. The compound of claim 14 , wherein R 3 is isopropyl.
16. The compound of claim 14 , wherein R 5 is Cl, F, or Me.
17. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
18. A kit comprising:
the compound of claim 1 ; and
a container housing the compound.